Vernalis Slashes jobs After Setback | Chemical & Engineering News
Volume 86 Issue 8 | p. 18 | Concentrates
Issue Date: February 25, 2008

Vernalis Slashes jobs After Setback

Department: Business

Vernalis, a British biopharmaceutical company, is cutting its staff from 210 people to about 90 and is closing its clinical development operations in Canada. Vernalis will also settle an $82 million loan with its partner, Endo Pharmaceuticals. The news, which follows FDA's refusal to approve its drug Frova for the treatment of menstrual migraine, is spurring speculation that the company may be a takeover target. Vernalis currently has drug candidates in clinical trials for Parkinson's disease, ischemic stroke, neuropathic pain, and obesity. It also has an R&D collaboration with Biogen Idec on a Parkinson's disease drug and separate ventures with Novartis and Servier on cancer therapies.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment